Call me shocked. I would think the insurance industry would use these data to determine who they will insure (clean gene people) and who they won’t (people with “bad” genes)...
“Call me shocked. I would think the insurance industry would use these data to determine who they will insure (clean gene people) and who they won’t (people with “bad” genes)...”
Indeed, there would also be no shock if it was determined that the insurance industry was a large consumer of “private” ancestry type DNA records (under the table of course).
This wording in the article is also suspect...
As of November 1, UnitedHealthcare began covering “whole exome sequencing for patients where clinical presentation is non-specific and does not fit a well-defined syndrome.”
Clinical presentation..... well-defined syndrome...
These would still be tested for using current, expensive, progressive testing regimen which would keep premiums high dollars flowing to the insurance companies.
Two things medicine will likely not stand for...
Complete diagnostic process (whole body, soup to nuts in a single pass) as opposed to the diagnostic track/ala cart expensive and clunky methods currently in practice.
and
a cure (read gone, never coming back, never an issue again) for anything.
.02
YMMV
KYPD